Comparison of biochemical markers of bone remodelling in the assessment of the effects of alendronate on bone in postmenopausal osteoporosis
| Autor: | J.J. Štĕpán, J. Vokrouhlická |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
musculoskeletal diseases medicine.medical_specialty Bone disease Clinical Biochemistry Osteoporosis Urology Biochemistry Bone remodeling Placebos Double-Blind Method N-terminal telopeptide Bone Density Internal medicine Humans Medicine Aged Femoral neck Bone mineral Alendronate biology business.industry Alendronic acid Biochemistry (medical) General Medicine Middle Aged medicine.disease Postmenopause Endocrinology medicine.anatomical_structure Osteocalcin biology.protein Female Bone Remodeling business Biomarkers medicine.drug |
| Zdroj: | Clinica Chimica Acta. 288:121-135 |
| ISSN: | 0009-8981 |
| DOI: | 10.1016/s0009-8981(99)00151-5 |
| Popis: | The effects of alendronate treatment on biochemical markers of bone remodelling and bone mineral density (BMD) were studied in 30 Caucasian women (postmenopausal for at least 3 years, age 42–76 years, with BMD of the lumbar spine at least 2 S.D. below the mean for mature, premenopausal women). The patients were randomly assigned to receive alendronate (10 mg/day) or placebo for 12 months (double blind). The study was subsequently extended to a second year of open alendronate treatment. The treatment with alendronate resulted in a significant and progressive increase in BMD of the lumbar spine and femoral neck. Under the treatment, the maximal decrease of biochemical markers of bone remodelling (osteocalcin in plasma, bone-specific alkaline phosphatase, N-terminal propeptide of type I procollagen and C-terminal telopeptide of type I collagen in serum, and cross-linked amino-terminal N-telopeptide and total hydroxyproline in urine) was observed at 6 months with no further change during the 2-year period. There were no significant differences in discriminating between patients treated for 1 year with alendronate or placebo using either the percentage change in spine BMD at month 12, or a single measurement of the marker at month 6, or log (percent of baseline at month 6 of value of the marker). In this respect, the power of all the biochemical markers were comparable. The markers are a valuable adjunct to the measurements of BMD, especially in the patients not showing an increase of 3% or more at the lumbar spine BMD after 1 year of treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect